Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Positron Emission Tomography01:29

Positron Emission Tomography

4.4K
Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
4.4K
Brain Imaging01:14

Brain Imaging

278
Brain imaging technologies provide critical insights into both the structure and function of the human brain, enabling medical professionals and researchers to diagnose, study, and treat neurological disorders or psychiatric disorders more effectively.
These technologies include computerized axial tomography (CAT or CT scans), positron-emission tomography (PET scans),  magnetic resonance imaging (MRI),  functional magnetic resonance imaging (fMRI), and Transcranial Magnetic...
278
Imaging Studies II: Positron Emission Tomography and Scintigraphy01:25

Imaging Studies II: Positron Emission Tomography and Scintigraphy

217
Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET
217

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Abdominal adiposity and Alzheimer's disease imaging markers across sex and race at midlife.

Journal of Alzheimer's disease : JAD·2026
Same author

Mesoscale CISS imaging for the detection of dural defects in spinal CSF leaks: A retrospective case series.

Headache·2026
Same author

Usage and positivity rates of Alzheimer's disease biomarkers in a memory clinic.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Vision Transformer-Based Segmentation of Abdominal Subcutaneous and Visceral Fat on MRI.

Journal of imaging informatics in medicine·2026
Same author

Association between retinal neurodegeneration assessed by optical coherence tomography and PET-detected cerebral amyloid burden in Alzheimer's disease: A systematic review.

Journal of Alzheimer's disease : JAD·2026
Same author

Brain microstructural alterations in COVID-19: a systematic review of diffusion weighted imaging studies.

Brain imaging and behavior·2026

Related Experiment Video

Updated: Aug 19, 2025

Radiotracer Administration for High Temporal Resolution Positron Emission Tomography of the Human Brain: Application to FDG-fPET
09:03

Radiotracer Administration for High Temporal Resolution Positron Emission Tomography of the Human Brain: Application to FDG-fPET

Published on: October 22, 2019

10.2K

Brain PET Imaging: Frontotemporal Dementia.

Joshua Ward1, Maria Ly1, Cyrus A Raji2

  • 1Division of Neuroradiology, Mallinckrodt Institute of Radiology, Washington University in Saint. Louis, Saint Louis, MO 63130, USA.

PET Clinics
|November 28, 2022
PubMed
Summary

Brain PET imaging is valuable for diagnosing frontotemporal dementia (FTD) and related neurodegenerative disorders. Combining 18F-FDG-PET with MRI enhances diagnostic accuracy for FTD.

Keywords:
(18)F-FDG-PETAlzheimer disease (AD)Amyloid-PETFrontotemporal dementia (FTD)MRINeurodegenerative disorders fused-in-sarcoma protein (FUS)SPECTTau-PET

More Related Videos

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
05:17

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

Published on: April 18, 2025

304
Semi-quantitative Assessment Using [18F]FDG Tracer in Patients with Severe Brain Injury
09:58

Semi-quantitative Assessment Using [18F]FDG Tracer in Patients with Severe Brain Injury

Published on: November 9, 2018

7.7K

Related Experiment Videos

Last Updated: Aug 19, 2025

Radiotracer Administration for High Temporal Resolution Positron Emission Tomography of the Human Brain: Application to FDG-fPET
09:03

Radiotracer Administration for High Temporal Resolution Positron Emission Tomography of the Human Brain: Application to FDG-fPET

Published on: October 22, 2019

10.2K
Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
05:17

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

Published on: April 18, 2025

304
Semi-quantitative Assessment Using [18F]FDG Tracer in Patients with Severe Brain Injury
09:58

Semi-quantitative Assessment Using [18F]FDG Tracer in Patients with Severe Brain Injury

Published on: November 9, 2018

7.7K

Area of Science:

  • Neuroimaging
  • Neurology
  • Nuclear Medicine

Background:

  • Frontotemporal dementia (FTD) presents with overlapping symptoms, complicating diagnosis.
  • Accurate diagnosis is crucial for appropriate patient management and treatment.
  • Neuroimaging plays a key role in differentiating FTD from other neurological and psychiatric conditions.

Purpose of the Study:

  • To evaluate the diagnostic value of various Positron Emission Tomography (PET) techniques in neurodegenerative disorders, particularly FTD.
  • To compare the efficacy of PET imaging with other diagnostic modalities like MRI and SPECT.
  • To explore the role of specific PET tracers (e.g., Tau-PET, amyloid-PET) in FTD diagnosis and differential diagnosis.

Main Methods:

  • Review of existing literature on brain PET imaging for neurodegenerative disorders.
  • Analysis of studies comparing 18F-FDG-PET, Tau-PET, and amyloid-PET with structural MRI and SPECT.
  • Focus on diagnostic sensitivity and specificity in FTD.

Main Results:

  • 18F-FDG-PET shows improved sensitivity and specificity over structural MRI for FTD diagnosis.
  • Optimal diagnostic outcomes are achieved by combining 18F-FDG-PET with MRI.
  • PET imaging is more sensitive than SPECT for FTD diagnosis, often serving as a supplementary tool.
  • Tau-PET and amyloid-PET are primarily used to differentiate FTD from Alzheimer's disease, mainly in research.

Conclusions:

  • Brain PET, particularly 18F-FDG-PET, significantly aids in diagnosing FTD and related neurodegenerative conditions.
  • The combination of 18F-FDG-PET and MRI offers superior diagnostic performance for FTD.
  • While PET is a valuable supplement to clinical evaluation and other imaging, advanced PET tracers like Tau-PET and amyloid-PET have specific, research-oriented roles in FTD diagnosis.